Philippe Moreau
CHU de Nantes
Philippe Moreau, MD, serves as Professor of Clinical Hematology and head of the translational research program in hematology and oncology, at the University Hospital of Nantes, France. Professor Moreau’s clinical interests are focused on multiple myeloma and its treatment with high-dose therapy and novel agents.
Professor Moreau is the chairman of the Intergroupe Francophone du Myélome (IFM).
He was a member of the organizing committee for the 2011 International Myeloma Workshop in Paris.
He is vice-president of International Myeloma Society (IMS) since 2019, and he is a member of the steering committee of the International Myeloma Working Group (IMWG) since 2013. He has served as the principal investigator or co-PI of many international randomized phase 3 clinical trials: Tourmaline (Ixazomib for relapsed myeloma), Aspire (Carfilzomib for relapsed myeloma), Endeavor (Carfilzomib for relapsed myeloma), Stratus (Pomalidomide for relapsed myeloma), Pollux (Daratumumab for relapsed myeloma), Arrow (weekly versus biweekly Carfilzomib for relapsed myeloma) or Cassiopeia (Daratumumab for frontline therapy in transplant eligible patients).
His research is widely published. Professor Moreau has authored or coauthored more than 300 peer-reviewed articles that have appeared in high impact factor journals including, the New England Journal of Medicine, Journal of Clinical Oncology, The Lancet, The Lancet Oncology, and Blood. He is a member of the editorial boards of Blood, and Blood Cancer Journal and is frequently invited to speak at international hematologic oncology meetings.
Professor Moreau received in 2018 the Robert A. Kyle lifetime achievement award.
Professor Moreau is the chairman of the Intergroupe Francophone du Myélome (IFM).
He was a member of the organizing committee for the 2011 International Myeloma Workshop in Paris.
He is vice-president of International Myeloma Society (IMS) since 2019, and he is a member of the steering committee of the International Myeloma Working Group (IMWG) since 2013. He has served as the principal investigator or co-PI of many international randomized phase 3 clinical trials: Tourmaline (Ixazomib for relapsed myeloma), Aspire (Carfilzomib for relapsed myeloma), Endeavor (Carfilzomib for relapsed myeloma), Stratus (Pomalidomide for relapsed myeloma), Pollux (Daratumumab for relapsed myeloma), Arrow (weekly versus biweekly Carfilzomib for relapsed myeloma) or Cassiopeia (Daratumumab for frontline therapy in transplant eligible patients).
His research is widely published. Professor Moreau has authored or coauthored more than 300 peer-reviewed articles that have appeared in high impact factor journals including, the New England Journal of Medicine, Journal of Clinical Oncology, The Lancet, The Lancet Oncology, and Blood. He is a member of the editorial boards of Blood, and Blood Cancer Journal and is frequently invited to speak at international hematologic oncology meetings.
Professor Moreau received in 2018 the Robert A. Kyle lifetime achievement award.
讲座视频：0
论文摘要：1
1050
0
0
| 日期 | 时间 | 会场 | Session | 角色 | 讲题 |
|---|---|---|---|---|---|
| 2020-09-26 | 09:30-10:00 | 主会场/大宴会厅 |
大会报告 17 |
讲者 | Management of Multiple Myeloma in the Era of Novel Agents |
中华医学会血液学分会 中华医学会学术会务部
地 址：北京东四西大街42号 电 话：400-008-5413、18612976547
电子邮件：cmacsh@126.com、10075882@qq.com
大会官方网站内容未经允许，禁止拷贝或转载本站内容，禁止建立类似会议注册页面，否则追究法律责任！
美迪康会务通